How are advances in radioligand therapy shaping the treatment of neuroendocrine tumours, and what does recent trial evidence tell us? What are the key considerations for patient selection, sequencing, and safety?

In this podcast moderated by the Oncology Brothers, Drs Rohit and Rahul Gosain are joined by medical oncologist Dr Heloisa Soares and nuclear medicine physician Prof. Ken Herrmann to explore the evolving role of targeted radioligand therapy in NETs.

As the conversation unfolds, the experts discuss evidence from recent studies, including the COMPETE trial, share practical insights on multidisciplinary decision-making, and highlight future directions such as the potential for first-line treatment with radioligand therapy.

Key clinical takeaways:

• Pair the right patient with the right treatment using an understanding of the key clinical studies

• The role of PRRT as a very effective 2nd-line treatment was consolidated by the COMPETE study data

• The best outcomes are achieved through multi-disciplinary collaborations that include the patient

Listen to the audio version of this conversation on Spotify, Apple, or on the COR2ED website, where you can also download the accompanying transcript and infographic: https://cor2ed.com/net-connect/programmes/targeted-radiopharmaceutical-treatment-nets/?media=0

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect/?viewAsMember=true

X: https://x.com/net_connectinfo

This content is intended for healthcare professionals only.

This podcast is supported by an Independent Education Grant from ITM.

This podcast is developed by cor2ed.com

Published September 2025

Metastatic pancreatic ductal adenocarcinoma (mPDAC) is notoriously aggressive with a poor prognosis. It is often diagnosed late, and by this time, surgery is usually not an option. Median overall survival without treatment is just a few months but with systemic chemotherapy this can be improved.

This video includes the highlights from a video podcast where medical oncologists Prof Shubham Pant and Prof Efrat Dotan discuss how to choose and optimise the different chemotherapeutic options at first and second line.

Key clinical takeaways:

• mPDAC is notoriously aggressive with a poor prognosis. Patients are generally diagnosed with advanced-stage disease and require treatment with chemotherapy as soon as possible
• Frontline regimens should be individualised based on performance status, comorbidities, and risk of neuropathy; FOLFIRINOX, NALIRIFOX, and gemcitabine/nab-paclitaxel all offer survival benefit with distinct toxicity profiles
• Choice of 2nd line treatment should be guided by prior regimen and patient fitness
• Dose modification and alternative scheduling are standard in real-world practice and are used to maintain dose intensity while improving tolerability and reducing adverse events

You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/gi-connect/programmes/tackling-mpdac/?media=0

Or watch on YouTube: https://youtu.be/8YxRnjOYUv4

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/giconnect

X: https://x.com/giconnectInfo

This content is intended for healthcare professionals only.

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Ipsen USA.

This podcast is developed by cor2ed.com

Published May 2025

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.